source
- Merck says 2027 will focus on pipeline and new product launches despite recent trial winsMerck's chief financial officer said the company views 2027 as another year of investment, emphasizing its expanding pipeline and upcoming product launches rather than short‑term margin growth. Th…
- Genmab's bispecific combo with Keytruda halves death risk in phase 3 head‑neck cancer trialGenmab announced interim results from its phase 3 LiGeR-HN1 study, showing that adding the bispecific antibody petosemtamab to Merck's Keytruda significantly improved outcomes for patients with PD-…